Sirolimus, a generic medication with the brand name Rapamune, is a member of the group of medications known as mTOR inhibitors. Tacrolimus and rapamycin are two further types of comparable drugs that function by blocking this route. A medication called Rapamune (Sirolimus) decreases the body's capacity to reject organ transplants by reducing or preventing the production of specific proteins by cells. Lupus nephritis, renal transplant rejection prevention, and use in transplant patients have all been authorised. It is a member of the pharmacological class known as rapamycin analogues.
The T cell activation that leads to organ rejection following transplantation is prevented with Sirolimus Rasamune suppresses the immune system. Mammalian target of rapamycin (mTOR), a serine/threonine-specific protein kinase that controls cell growth, proliferation, and survival, is its main mode of action. Due to its ability to regulate ageing and preserve a healthy glucose homeostasis, mTOR is a crucial therapeutic target for a number of disorders. Since mTOR signalling pathways are constitutively active in many forms of human cancer, mTOR has attracted more interest in the fight against cancer in particular.
Read More @ https://cmibloginsight.blogspot.com/2022/08/sirolimus-plays-key-role-in-prevention.html
